Overview

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Status:
Completed

Trial end date:
2006-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate